Status:
UNKNOWN
Simultaneous Integrated Boost vs. Routine IMRT in Limited-stage Small-cell Lung Cancer
Lead Sponsor:
Chinese Academy of Medical Sciences
Conditions:
Small-cell Lung Cancer
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
Thoracic radiotherapy concurrent with chemotherapy stands for the standard regime for limited staged small cell lung cancer. Involved node radiation（INF） replaced elective node irradiation（ENI） as the...
Detailed Description
All patients recruited divided into two arms：SIB-IMRT or routine IMRT，in the routine arm，the prescription dose was 60Gy/2Gy/30f，and in the SIB arm ，60Gy was given to the field of the tumor and metasta...
Eligibility Criteria
Inclusion
- 18-70 years old,KPS≥80
- pathological small cell lung cancer
- staged as limited disease SCLC（contralateral hilar invasion not included）
- receive radiotherapy concurrent or sequential with chemotherapy，if induction chemotherapy，got PR or SD
- no other tumors
- No serious medical diseases and dysfunction of major organs
- understand this study，able to complete the treatment，accept the following up and sign the informed consent
- Contraception in women of childbearing age.
Exclusion
- other malignant tumor（historically or simultaneously）curable non-melanoma skin cancer and cervical carcinoma in situ not included
- Uncontrolled heart disease or myocardial infarction within 6 months
- History of mental illness
- Pregnancy or Lactation
- uncontrolled diabetes、hypertension
Key Trial Info
Start Date :
July 20 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 20 2021
Estimated Enrollment :
350 Patients enrolled
Trial Details
Trial ID
NCT04500145
Start Date
July 20 2017
End Date
October 20 2021
Last Update
February 1 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China, 100021